Marvin L. Meistrich, PhD, Oral History Interview, May 2, 2017
Files
Download Full Interview Transcript (815 KB)
Loading...
Description
Major Topics Covered:
- Personal background
- Educational path
- Research: spermatid nuclear proteins, spermatogenesis, impact of chemotherapy on oncofertility; cryopreservation and transplantation
- Attitudes toward addressing issues of oncofertility and sperm banking at MD Anderson
- Research culture
- The Department of Experimental Radiation Oncology, history of
- Institutional change and growth
- Retirement process
Publication Date
5-2-2017
Publisher
The Historical Resources Center, Research Medical Library, The University of Texas Cancer Center
City
Houston, Texas
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Topics Covered
University of Texas MD Anderson Cancer Center, UT MD Anderson Cancer Center, University of Texas System. M.D. Anderson Cancer Center, M.D. Anderson Hospital and Tumor Institute at Houston, University of Texas M.D. Anderson Cancer Center, M.D. Anderson Hospital and Tumor Institute
Disciplines
History of Science, Technology, and Medicine | Oncology | Oral History
Recommended Citation
Meistrich, Marvin L. PhD and Rosolowski, Tacey A. PhD, "Marvin L. Meistrich, PhD, Oral History Interview, May 2, 2017" (2017). Interview Sessions. 166.
https://openworks.mdanderson.org/mchv_interviewsessions/166
Conditions Governing Access
Open
About the Interview
About the Interview Subject:
Marvin L. Meistrich, PhD, (10 October 1941, Brooklyn, New York) came to MD Anderson in 1772 as a 1972 as an Assistant Biophysicist and Assistant Professor in the Department of Experimental Radiotherapy in what was then called the Division of Radiotherapy.
Today he is a Professor in Department of Experimental Radiation Oncology, in the Division of Radiation Oncology. Dr. Meistrich is also a member of the Center for Radiation Oncology Research Group.
He is known for his work on spermatogenesis and has made a major contribution to categorizing the effects of chemotherapy treatments on male fertility. He retired to a partial appointment in 1012, retiring fully in 2017. In this interview, Dr. Meistrich speaks at length about his research into spermatogenesis, about collaborations that led to changes in patient care, and about the environment for this research and care at MD Anderson. He also speaks about his patient experiences and receiving an incorrect cancer diagnosis.